Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.
about
Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series)Pathobiology of pulmonary arterial hypertension and right ventricular failurePrinciples of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in diseaseMethods for measuring right ventricular function and hemodynamic coupling with the pulmonary vasculatureMetabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effectRole of oxidized lipids in pulmonary arterial hypertensionEmerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertensionA Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human LungEmerging Metabolic Therapies in Pulmonary Arterial Hypertension.The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.Pulmonary 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake is low in treated patients with idiopathic pulmonary arterial hypertensionValue of impedance cardiography during 6-minute walk test in pulmonary hypertension.Metabolomic heterogeneity of pulmonary arterial hypertensionThe role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertensionRescuing the BMPR2 signaling axis in pulmonary arterial hypertensionGenetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming.Commentary: The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.Pulmonary hypertension in parenchymal lung disease.Profiling the role of mammalian target of rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension.Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia(1)H NMR-Based Analysis of Serum Metabolites in Monocrotaline-Induced Pulmonary Arterial Hypertensive Rats.Disruption of endothelial cell mitochondrial bioenergetics in lambs with increased pulmonary blood flow.Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.Inhibition of fatty acid synthase is protective in pulmonary hypertension.Metabolomic profiling to dissect the role of visceral fat in cardiometabolic healthNovel approaches to pulmonary arterial hypertension drug discoveryConstitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension.Thoracic [18F]fluorodeoxyglucose uptake measured by positron emission tomography/computed tomography in pulmonary hypertension.Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension.Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice.Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to HypoxiaMammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.Relevant issues in the pathology and pathobiology of pulmonary hypertension.Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.A process-based review of mouse models of pulmonary hypertension.Recent advances in metabolic imaging.
P2860
Q26772286-CAF337AD-C088-4E56-854D-2591A6DA6349Q26821779-EF4EC504-CA66-4ADC-BB0B-8DDB1E244E9EQ26859449-BE8B2277-FA78-4DC7-AA14-354AB4A4B87AQ27013992-C4624DE5-E1CD-41A8-9E1A-8264147C710BQ27024293-A10BDCB8-0AA4-4C6E-A421-1488D369D9C9Q28078566-44BA4206-5A9D-439D-8BD2-50A7F244A1F3Q28083183-AE8B23D2-4773-4A47-995F-DB231B2DB4CFQ28547572-C0A3C2B0-A8A7-49D7-9F36-71C29279F8F9Q33608219-EE649EEB-AD5D-431F-858F-610E2C2AEB49Q33705883-C3793D13-5E36-48AE-ABE3-EE1088425CB0Q33806143-066A5421-DEA0-4EC6-9BC1-79A01A3FD12DQ34865736-281158FF-AD04-49AF-85E7-0AC787B5C52DQ35095550-F40223FE-AF34-47B8-9BF9-0F44F5ABF148Q35115789-3BE3840A-34B0-4E62-81AE-ED21C23CBE1FQ35115808-8F49CCE4-F9EA-44A1-A65F-685EC352D4F9Q35410950-E522F09C-87B1-43D8-9B5F-7C479B241CCAQ35695350-F48326EE-FB2D-47CC-A240-6851093CD9DAQ36108056-62BE4148-9AC5-4543-9EDF-D31A01A2F82CQ36175258-B7DFAE61-9FD4-4247-9A5E-24D912C7169FQ36328903-C9C6E577-A213-4B8D-9EE6-2C44C0F42143Q36352098-A2826F87-1DA3-425A-844C-00A4CB5DBF40Q36490033-8992D52E-8979-4F40-AEEF-58290B736C39Q36555906-8C1D24CA-5EA1-4DA6-A540-7DCE8E9410B4Q36747218-31242F33-EB5D-43AB-8431-EE8C2A46D359Q36752368-7D891241-933C-4B77-A8BE-B127C76FA30FQ36788720-398272A7-64A3-4178-9D7B-1418A539160BQ36941262-D9F6664A-F303-4CB8-A8C8-10B285A0906FQ37023957-E131FF2B-FE7C-4A90-802C-5C72F8514896Q37066778-7BA1F15F-2890-48DB-BC8E-8A83A0F4D730Q37088266-5CD5D473-AE80-458C-8EAD-5551AD3CA86EQ37205206-52EDCEB9-5182-4A3E-BC7D-BBB86C569F45Q37216215-78F7464B-A790-4990-961C-8F07B96E721CQ37305448-0976F198-076F-42D0-9512-3AFAF1F53415Q37596437-359AB698-BB30-46CA-A292-A2687005DDF8Q37653867-D306D5F3-0B0A-4981-BBAC-B9D5B865E29EQ37670612-95BCF0BA-86E0-475D-8B2D-6BD9A5DDE633Q37673917-63439EF6-1865-4FD3-BB65-C797E35D4574Q37705261-F6497292-52C6-4125-B19C-67A26ECAF0CDQ38078369-9ACC82A8-63E3-49FC-A3E2-6944D4EE9076Q38156683-4CA0A96A-0A61-4445-94D1-D4E9EB2FA210
P2860
Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@en
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@nl
type
label
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@en
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@nl
prefLabel
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@en
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@nl
P2093
P2860
P1476
Targeting energetic metabolism ...... ent of pulmonary hypertension.
@en
P2093
Brian B Graham
Laura A Davis
Rubin M Tuder
P2860
P304
P356
10.1164/RCCM.201108-1536PP
P407
P577
2011-11-10T00:00:00Z